Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $61.89 Average Price Target from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $61.8889.

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright upped their target price on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Piper Sandler increased their price target on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 26th. Finally, Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Michael S. Perry sold 16,250 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the transaction, the director directly owned 115,240 shares in the company, valued at $7,033,097.20. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Richard Anzalone sold 130,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the completion of the sale, the chief executive officer directly owned 3,971,255 shares in the company, valued at approximately $273,420,906.75. The trade was a 3.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 368,736 shares of company stock valued at $23,670,228 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ARWR. Cantor Fitzgerald L. P. lifted its position in shares of Arrowhead Pharmaceuticals by 14.7% in the third quarter. Cantor Fitzgerald L. P. now owns 19,500 shares of the biotechnology company’s stock valued at $673,000 after buying an additional 2,500 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $444,000. Keystone Financial Group bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at $276,000. CANADA LIFE ASSURANCE Co lifted its holdings in Arrowhead Pharmaceuticals by 11.7% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 129,958 shares of the biotechnology company’s stock valued at $4,389,000 after purchasing an additional 13,653 shares during the last quarter. Finally, Woodline Partners LP boosted its position in Arrowhead Pharmaceuticals by 34.0% during the third quarter. Woodline Partners LP now owns 1,000,158 shares of the biotechnology company’s stock worth $34,495,000 after purchasing an additional 254,002 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $69.62 on Friday. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $72.36. The company’s fifty day simple moving average is $52.38 and its 200-day simple moving average is $33.56. The firm has a market cap of $9.46 billion, a PE ratio of -870.14 and a beta of 1.28. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.